Affiliation:
1. Cardiology Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences
2. Novosibirsk State Medical University
3. State Novosibirsk Regional Medical and Physical Education Dispensary
Abstract
Objective. To study the pathogenetic and prognostic role of cytokines (tumor necrosis factor-α (TNF-α) and interleukin-1β (IL-1β)) in the development of anthracycline-induced chronic heart failure (CHF).Material and Methods. A total of 176 women with breast cancer who received anthracycline antibiotics as a part of polychemotherapy regimens were examined. Upon examination, the patients in remission were divided into two groups within 12 months after the completion of chemotherapy: patients with the development of cardiotoxic remodeling (group 1, n = 52) and women with preserved cardiac function (group 2, n = 124). All patients received echocardiography study before, during, and after chemotherapy. Biochemical blood tests were done to determine the levels of TNF-α and IL-1β before chemotherapy, immediately after it, and 12 months after chemotherapy completion. Determination of polymorphisms of the TNF-α (–308G/A, rs1800629) and IL-1β genes (+3953, rs1143634) was carried out by polymerization chain reaction.Results. A higher level of TNF-α and IL-1β in group 1 was associated with the development of heart failure 12 months after the end of chemotherapy. The level of TNF-α over 7.5 pg/mL after the completion of chemotherapy allowed to predict the development of cardiovascular complications in women receiving anthracycline therapy with sensitivity of 44.2% and specificity of 75.8% (AUS = 0.600; 95% CI = 0.524–0.673; p = 0.035). The study did not reveal any significant differences in the frequency distribution for genotypes of 308G/A polymorphism (rs1800629) of the TNF-α gene and +3953 (rs1143634) polymorphism of the IL-1β gene in the studied groups.Conclusion. Patients with breast cancer who developed anthracycline-induced heart failure 12 months after the end of chemotherapy had the increased levels of TNF-α and IL-1β suggesting the pathogenetic role of proinflammatory cytokines in the development of cardiac injury during anthracycline therapy.
Publisher
Cardiology Research Institute
Reference22 articles.
1. DeSantis C.E., Lin C.C., Mariotto A.B., Siegel R.L., Stein K.D., Kramer J.L. et al. Cancer treatment and survivorship statistics, 2014. CA Cancer J. Clin. 2014;64(4):252–271. DOI: 10.3322/caac.21235.
2. Force T., Kolaja K.L. Cardiotoxicity of kinase inhibitors: the prediction and translation of preclinical models to clinical outcomes. Nat. Rev. Drug. Discov. 2011;10(2):111–126. DOI: 10.1038/nrd3252.
3. Vasyuk Yu.A., Shkolnik E.L., Nesterov V.V. Shkolnik L.D., Varlan G.V. Cardiooncology: Current aspects of prevention of anthracycline toxicity. Kardiologiia. 2016;56(12):72–79 (In Russ.). DOI: 10.18565/cardio.2016.12.72-79.
4. Zamorano J.L., Lancellotti P., Munoz D. R., Aboyans V., Asteggiano R., Galderisi M. et al. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur. Heart. J. 2016;37(36):2768–2801. DOI: 10.1093/eurheartj/ehw211.
5. Almuwaqqat Z., Meisel J.L., Barac A., Parashar S. Breast cancer and heart failure. Heart Fail. Clin. 2019;15(1):65–75. DOI: 10.1016/j.hfc.2018.08.007.
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献